(BCAX) Bicara Therapeutics Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.342m USD | Total Return: 38.4% in 12m
Avg Turnover: 8.46M
Warnings
Interest Coverage Ratio -3.7 is critical
Altman Z'' -9.72 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Bicara Therapeutics Inc. (BCAX) is a Boston-based, clinical-stage biopharmaceutical firm focused on engineering bifunctional therapies to treat solid tumors. The company’s primary asset, ficerafusp alfa, is a dual-action antibody designed to simultaneously inhibit the epidermal growth factor receptor (EGFR) and neutralize transforming growth factor beta (TGF-β) within the tumor microenvironment.
Operating within the biotechnology sector, the company utilizes a precision medicine business model characterized by high research and development intensity and reliance on clinical trial milestones. Bifunctional antibodies represent an evolving class of oncology therapeutics aimed at overcoming drug resistance mechanisms that often limit the efficacy of single-target monoclonal antibodies.
Investors should examine detailed pipeline data on ValueRay to better understand the companys clinical trajectory. Bicara Therapeutics was incorporated in 2018 and continues to advance its lead candidate through various stages of clinical evaluation.
- Clinical trial results for ficerafusp alfa in head and neck cancer
- Regulatory approval milestones for bifunctional antibody therapies in solid tumors
- Partnership agreements with major pharmaceutical firms for pipeline co-development
- R&D expenditure and cash runway sustainability through late-stage clinical trials
- Competitive landscape shifts within the EGFR and TGF-beta inhibitor markets
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA -2.58 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.21 > 3% & CFO -116.2m > Net Income -157.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.7m) vs 12m ago 11.50% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -3.65 > 6 (EBITDA TTM -173.9m / Interest Expense TTM 47.7m) |
| A: 0.91 (Total Current Assets 544.9m - Total Current Liabilities 39.3m) / Total Assets 553.6m |
| B: -0.75 (Retained Earnings -415.2m / Total Assets 553.6m) |
| C: -0.34 (EBIT TTM -174.1m / Avg Total Assets 515.8m) |
| D: -10.48 (Book Value of Equity -415.4m / Total Liabilities 39.6m) |
| Altman-Z'' = -9.72 = D |
As of May 24, 2026, the stock is trading at USD 21.68 with a total of 333,148 shares traded.
Over the past week, the price has changed by +7.17%,
over one month by -8.25%,
over three months by +32.20% and
over the past year by +38.44%.
Bicara Therapeutics Common has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy BCAX.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.5 | 45.1% |
Revenue TTM = 0.0 USD
EBIT TTM = -174.1m USD
EBITDA TTM = -173.9m USD
Long Term Debt = 301k USD (estimated: total debt 1.44m - short term 1.14m)
Short Term Debt = 1.14m USD (from shortTermDebt, last quarter)
Debt = 1.44m USD (from shortLongTermDebtTotal, last quarter) (leases 1.44m already included)
Net Debt = -538.3m USD (calculated: Debt 1.44m - CCE 539.8m)
Enterprise Value = 804.0m USD (1.34b + Debt 1.44m - CCE 539.8m)
Interest Coverage Ratio = -3.65 (Ebit TTM -174.1m / Interest Expense TTM 47.7m)
EV/FCF = -6.90x (Enterprise Value 804.0m / FCF TTM -116.6m)
FCF Yield = -14.50% (FCF TTM -116.6m / Enterprise Value 804.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.45 (Enterprise Value 804.0m / Total Assets 553.6m)
Interest Expense / Debt = 3.31k% (Interest Expense 47.7m / Debt 1.44m)
Taxrate = 21.0% (US default 21%)
NOPAT = -137.5m (EBIT -174.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.85 (Total Current Assets 544.9m / Total Current Liabilities 39.3m)
Debt / Equity = 0.00 (Debt 1.44m / totalStockholderEquity, last quarter 514.0m)
Debt / EBITDA = 3.10 (negative EBITDA) (Net Debt -538.3m / EBITDA -173.9m)
Debt / FCF = 4.62 (negative FCF - burning cash) (Net Debt -538.3m / FCF TTM -116.6m)
Total Stockholder Equity = 438.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.50% (Net Income -157.3m / Total Assets 553.6m)
RoE = -18.43% (Net Income TTM -157.3m / Total Stockholder Equity 853.5m)
RoCE = -20.39% (EBIT -174.1m / Capital Employed (Equity 853.5m + L.T.Debt 301k))
RoIC = -27.27% (negative operating profit) (NOPAT -137.5m / Invested Capital 504.1m)
WACC = 12.29% (E(1.34b)/V(1.34b) * Re(12.30%) + (debt cost/tax rate unavailable))
Discount Rate = 12.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 6.15%
[DCF] Fair Price = unknown (Cash Flow -116.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.70 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.81 | Chg30d=N/A | Revisions=-45% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.83 | Chg30d=N/A | Revisions=-45% | Analysts=13
EPS current Year (2026-12-31): EPS=-3.40 | Chg30d=N/A | Revisions=-69% | GrowthEPS=-34.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.63 | Chg30d=N/A | Revisions=-64% | GrowthEPS=-6.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -69%